DDMODEL00000233: Zierhut_2008_Population PKPD model for Fc-osteoprotegerin in healthy postmenopausal women

  public model
Short description:
PK/PD model for Fc-OPG and urinary NTx bone marker. This model was coded from the original publication to be run in mrgsolve (https://www.github.com/metrumresearchgroup/mrgsolve).
Original code
  • Population PK-PD model for Fc-osteoprotegerin in healthy postmenopausal women.
  • Zierhut ML, Gastonguay MR, Martin SW, Vicini P, Bekker PJ, Holloway D, Leese PT, Peterson MC
  • Journal of pharmacokinetics and pharmacodynamics, 8/2008, Volume 35, Issue 4, pages: 379-399
  • Department of Bioengineering, University of Washington, Seattle, WA 98195-2255, USA.
  • Osteoporosis is a metabolic bone disease resulting from increased bone resorption and characterized by low bone mass that leads to increased bone fragility and risk of fracture, particularly of the hip, spine and wrist. Bone resorption is dependent on receptor activator of NF-kappa B ligand (RANKL), which binds to RANK receptor on preosteoclasts to initiate osteoclastogenesis and maintains osteoclast function and survival. To neutralize the effects of RANKL, the body naturally produces the protein osteoprotegerin (OPG), which acts as a decoy receptor for RANKL and contributes to bone homeostasis. We describe the piecewise development of a three-compartment pharmacokinetic model with both linear and Michaelis-Menten eliminations, and an indirect pharmacodynamic response model to describe the pharmacokinetics and pharmacodynamics, respectively, of the fusion protein, Fc-osteoprotegerin (Fc-OPG), in healthy postmenopausal women. Subsequently, model verification was performed and used to address study design questions via simulation. The model was developed using data from eight cohorts (n = 13 subjects/cohort; Fc-OPG:placebo = 10:3) classified by dose level (0.1, 0.3, 1.0, or 3.0 mg/kg) and route of administration (intravenous [IV] or subcutaneous [SC]). Fc-OPG serum concentrations and urinary N-telopeptide/creatinine ratios (NTX) following both IV and SC administration were available. The model provided an adequate fit to the observed data and physiologically plausible parameter estimates. Model robustness was tested via a posterior predictive check with the model performing well in most cases. Subsequent clinical trial simulations demonstrated that a single 3.0-mg/kg SC dose of Fc-OPG would be expected to produce, at 14 days post-dose, a median NTX percentage change from baseline of -45% (with a 95% prediction interval ranging from -34% to -60%). Lastly, model ruggedness was evaluated using local and global sensitivity analysis methods. In conclusion, the model selection and simulation strategies we applied were rigorous, useful, and easily generalizable.
Kyle Baron, Mike K Smith
Context of model development: Clinical end-point; Dose & Schedule Selection and Label Recommendation;
Discrepancy between implemented model and original publication: None that I know of.;
Model compliance with original publication: Yes;
Model implementation requiring submitter’s additional knowledge: No;
Modelling context description: Early dose selection.;
Modelling task in scope: simulation;
Nature of research: Early clinical development (Phases I and II);
Therapeutic/disease area: Endocrinology;
Annotations are correct.
This model is not certified.
  • Model owner: Kyle Baron
  • Submitted: Nov 18, 2016 9:56:30 PM
  • Last Modified: Mar 27, 2017 3:59:11 PM
Revisions
  • Version: 48 public model Download this version
    • Submitted on: Mar 27, 2017 3:59:11 PM
    • Submitted by: Mike K Smith
    • With comment: Edited model metadata online.
  • Version: 46 public model Download this version
    • Submitted on: Feb 9, 2017 11:04:54 AM
    • Submitted by: Mike K Smith
    • With comment: Model revised without commit message
  • Version: 45 public model Download this version
    • Submitted on: Nov 19, 2016 6:05:58 PM
    • Submitted by: Kyle Baron
    • With comment: Edited model metadata online.
  • Version: 43 public model Download this version
    • Submitted on: Nov 19, 2016 2:07:09 PM
    • Submitted by: Kyle Baron
    • With comment: Edited model metadata online.
  • Version: 41 public model Download this version
    • Submitted on: Nov 18, 2016 11:55:33 PM
    • Submitted by: Kyle Baron
    • With comment: Edited model metadata online.
  • Version: 23 public model Download this version
    • Submitted on: Nov 18, 2016 9:56:30 PM
    • Submitted by: Kyle Baron
    • With comment: Model revised without commit message
 
Help